Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Founders' Warrants, Warrants, and Free Shares Outstanding (Details)
|
|
|
|
|
|
|
|
|
|
|
|
|
12 Months Ended |
|
|
|
Jun. 27, 2023
shares
|
Apr. 21, 2021
€ / shares
|
Apr. 20, 2021
shares
€ / shares
|
Mar. 17, 2020
shares
€ / shares
|
Mar. 29, 2019
shares
€ / shares
|
Jul. 27, 2018
shares
€ / shares
|
Jan. 07, 2017
shares
€ / shares
|
Feb. 02, 2016
shares
€ / shares
|
Jun. 25, 2015
shares
€ / shares
|
Jun. 10, 2015
shares
€ / shares
|
Feb. 10, 2015
shares
€ / shares
|
Sep. 16, 2014
€ / shares
|
Dec. 31, 2025
shares
|
Dec. 31, 2025
shares
uSDollarPerEuro
|
Dec. 31, 2024
shares
|
Dec. 31, 2025
uSDollarPerEuro
|
Dec. 31, 2023
shares
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
4,985,304
|
4,985,304
|
4,936,540
|
|
4,172,089
|
| BSPCE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
296,100
|
296,100
|
467,067
|
|
557,367
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
75,867
|
|
0
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
(95,100)
|
|
(90,300)
|
|
|
| BSPCE 2015-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
|
|
|
|
71,650
|
|
0
|
|
0
|
|
|
| Grant price (in euro per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
| Exercise price (in euros per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
€ 18.57
|
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
67,750
|
|
68,100
|
| Number of awards, exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
71,650
|
71,650
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
67,750
|
|
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
(67,750)
|
|
(350)
|
|
|
| BSPCE 2015-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
|
|
|
53,050
|
|
|
0
|
|
0
|
|
|
| Grant price (in euro per share) | € / shares |
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
| Exercise price (in euros per share) | € / shares |
|
|
|
|
|
|
|
|
|
€ 20.28
|
|
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
27,350
|
|
28,400
|
| Number of awards, exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
53,050
|
53,050
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
27,350
|
|
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
(27,350)
|
|
(1,050)
|
|
|
| BSPCE 2016 Ordinary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
|
126,400
|
|
|
|
|
|
|
|
|
|
| Grant price (in euro per share) | € / shares |
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
| Exercise price (in euros per share) | € / shares |
|
|
|
|
|
|
|
€ 14.46
|
|
|
|
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
66,850
|
66,850
|
|
|
|
| Number of awards, exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
30,300
|
30,300
|
|
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
29,967
|
|
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
29,250
|
29,250
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
| BSPCE 2016 Performance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
|
129,250
|
|
|
|
|
|
|
|
|
|
| Grant price (in euro per share) | € / shares |
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
| Exercise price (in euros per share) | € / shares |
|
|
|
|
|
|
|
€ 14.46
|
|
|
|
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
55,200
|
55,200
|
|
|
|
| Number of awards, exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
42,900
|
42,900
|
|
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
42,900
|
|
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
31,150
|
31,150
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
| BSPCE 2017 Ordinary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
117,650
|
|
|
|
|
|
|
|
|
|
|
| Grant price (in euro per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in euros per share) | € / shares |
|
|
|
|
|
|
€ 15.93
|
|
|
|
|
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
94,050
|
94,050
|
|
|
|
| Number of awards, exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
3,000
|
3,000
|
|
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
3,000
|
|
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
20,600
|
20,600
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
| BSPCE 2017 P |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
80,000
|
|
|
|
|
|
|
|
|
|
|
| Grant price (in euro per share) | € / shares |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in euros per share) | € / shares |
|
|
|
|
|
|
€ 15.93
|
|
|
|
|
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
80,000
|
80,000
|
|
|
|
| Number of awards, exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
| BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
56,251
|
56,251
|
141,251
|
|
151,251
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
(85,000)
|
|
(10,000)
|
|
|
| BSA 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Exercise price (in euros per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
€ 17.67
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
10,000
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
(10,000)
|
|
|
| BSA 2015-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
|
|
|
|
26,000
|
|
0
|
|
0
|
|
|
| Grant price (in euro per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
€ 4.87
|
|
|
|
|
|
|
| Exercise price (in euros per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
€ 17.67
|
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
21,000
|
|
21,000
|
| Number of awards, exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
26,000
|
26,000
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
21,000
|
|
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
(21,000)
|
|
0
|
|
|
| BSA 2015-2 a |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
|
|
64,000
|
|
|
|
0
|
|
0
|
|
|
| Grant price (in euro per share) | € / shares |
|
|
|
|
|
|
|
|
€ 5.00
|
|
|
|
|
|
|
|
|
| Exercise price (in euros per share) | € / shares |
|
|
|
|
|
|
|
|
€ 19.54
|
|
|
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
64,000
|
|
64,000
|
| Number of awards, exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
64,000
|
64,000
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
64,000
|
|
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
(64,000)
|
|
0
|
|
|
| BSA 2018-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
5,820
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Grant price (in euro per share) | € / shares |
|
|
|
|
|
€ 2.36
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in euros per share) | € / shares |
|
|
|
|
|
€ 16.10
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
5,820
|
5,820
|
5,820
|
|
5,820
|
| Number of awards, exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| BSA 2019-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
18,000
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Grant price (in euro per share) | € / shares |
|
|
|
|
€ 1.15
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in euros per share) | € / shares |
|
|
|
|
€ 11.66
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
18,000
|
18,000
|
18,000
|
|
18,000
|
| Number of awards, exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| BSA 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
18,000
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Grant price (in euro per share) | € / shares |
|
|
|
€ 0.29
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in euros per share) | € / shares |
|
|
|
€ 6.59
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
18,000
|
18,000
|
18,000
|
|
18,000
|
| Number of awards, exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| BSA 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
48,103
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Grant price (in euro per share) | € / shares |
|
|
€ 2.95
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in euros per share) | € / shares |
|
€ 13.47
|
€ 13.47
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
14,431
|
14,431
|
14,431
|
|
14,431
|
| Number of awards, exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
33,672
|
33,672
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| AGA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
815,920
|
|
1,127,296
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
809,820
|
|
293,523
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
(5,700)
|
|
(17,853)
|
|
|
| AGA 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
293,776
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
293,523
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
(253)
|
|
|
| AGA 2023 - P1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
427,110
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
392,460
|
|
400,960
|
| Number of awards, exercised (in shares) | uSDollarPerEuro |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
392,060
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
392,060
|
392,060
|
0
|
|
|
| Number of awards lapsed or cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
35,050
|
35,050
|
|
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
400
|
|
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
(8,500)
|
|
|
| AGA 2023 - P2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of awards issued (in shares) |
439,210
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Number of awards outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
423,460
|
0
|
432,560
|
| Number of awards, exercised (in shares) | uSDollarPerEuro |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
417,760
|
|
| Awards exercised during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
417,760
|
417,760
|
0
|
|
|
| Number of awards lapsed or cancelled (in shares) | uSDollarPerEuro |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,450
|
|
| Number of awards lapsed or cancelled during the period (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
5,700
|
|
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
(5,700)
|
|
(9,100)
|
|
|